(Q42282187)

19 October 2017

title

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies (English)

1 reference

19 October 2017

4

Stefan Zeuzem

1 reference

19 October 2017

5

Fred Poordad

0 references

author name string

Richard J O Barnard

1

1 reference

19 October 2017

John A Howe

2

1 reference

19 October 2017

Robert A Ogert

3

1 reference

19 October 2017

Stuart C Gordon

6

1 reference

19 October 2017

Robert Ralston

7

1 reference

19 October 2017

Xiao Tong

8

1 reference

19 October 2017

Vilma Sniukiene

9

1 reference

19 October 2017

Julie Strizki

10

1 reference

19 October 2017

Desmond Ryan

11

1 reference

19 October 2017

Jianmin Long

12

1 reference

19 October 2017

Ping Qiu

13

1 reference

19 October 2017

Clifford A Brass

14

1 reference

19 October 2017

Janice Albrecht

15

1 reference

19 October 2017

Margaret Burroughs

16

1 reference

19 October 2017

Scott Vuocolo

17

1 reference

19 October 2017

Daria J Hazuda

18

1 reference

19 October 2017

language of work or name

English

0 references

publication date

19 July 2013

1 reference

19 October 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

19 October 2017

volume

444

1 reference

19 October 2017

issue

1-2

1 reference

19 October 2017

page(s)

329-336

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Boceprevir, an NS3 protease inhibitor of HCV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Boceprevir for untreated chronic HCV genotype 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Factors that predict response of patients with hepatitis C virus infection to boceprevir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Rapid emergence of protease inhibitor resistance in hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Global epidemiology of hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Characterization of resistance mutations against HCV ketoamide protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

Interferon-based therapy for chronic hepatitis C: current and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.029

10.1016/J.VIROL.2013.06.029

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference